X4 Pharmaceuticals, Inc (XFOR) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$2.60

From 52W high−41.11%

Volume602883.00

Market cap$272.65M

P/E (TTM)—

P/S (TTM)17.2x

Div yield—

Key dataOct 19, 2026

Open

$2.60

From 52W high

−41.11%

Volume

602883.00

Market cap

$272.65M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.8x

P/E (TTM)

—

RSI (14)

40.6

MomentumView details →

1D Return

+6.18%

YTD Return

−30.87%

SummaryUpdated Jun 1, 2026

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) is a late-stage clinical biopharmaceutical company founded in 2010 and headquartered in Boston, Massachusetts. The company went public in November 2017 and focuses on developing novel therapeutics for rare diseases. X4 Pharmaceuticals achieved a significant milestone in 2024 with the FDA approval and commercial launch of its lead drug XOLREMDI (mavorixafor) for WHIM syndrome, marking its transition from a pure development-stage company to a commercial-stage biopharmaceutical enterprise.

Ask drillr about X4 Pharmaceuticals, Inc →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−1.8x

EV/Sales

9.0x

P/S (TTM)

17.2x

P/B (TTM)

1.8x

ProfitabilityView details →

Gross Margin

81.22%

Net Margin

−568.80%

EBITDA Margin

−503.31%

ROE (TTM)

−57.98%

ROA (TTM)

−35.62%

Asset Turnover

0.06x

GrowthView details →

Revenue YoY

−51.65%

EPS YoY

+91.91%

FCF YoY

—

Revenue CAGR 3Y

+1273.21%

EPS CAGR 3Y

+66.55%

EBITDA YoY

+12.45%

MomentumView details →

1D Return

+6.18%

YTD Return

−30.87%

1Y Return

−11.94%

RSI (14)

40.6

vs 50D SMA

−21.16%

vs 200D SMA

−27.85%

Capital & dividendView details →

Debt/Equity

0.50x

Current Ratio

11.30x

Quick Ratio

11.02x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.13

EPS Surprise

26.14%

Beats (12Q)

8/12

Next Q EPS Est

−$0.19

Avg Surprise (4Q)

19.52%

Rev Surprise

263.88%

Financials snapshotView financials →

Revenue (TTM)

15.85M

Net Income (TTM)

−90.14M

Op. CF (TTM)

−83.74M

Next earningsNov 4, 2026 →

Latest newsMore news →

X4 Pharmaceuticals, Inc entered into a senior secured term loan facility of up to $150 million with K2 HealthVentures, replacing its prior loan agreement.11d ago

X4 Pharmaceuticals reported financial results for the second quarter ended June 30, 2026.74d ago

Similar companies

Cypherpunk Technologies Inc.CYPH Prelude Therapeutics IncorporatedPRLD Transcenta Holding Limited06628.HK Ocugen, Inc.OCGN Agenus Inc.AGEN Century Therapeutics, Inc.IPSC Find similar companies →

Latest newsMore news →

X4 Pharmaceuticals, Inc entered into a senior secured term loan facility of up to $150 million with K2 HealthVentures, replacing its prior loan agreement.11d ago X4 Pharmaceuticals reported financial results for the second quarter ended June 30, 2026.74d ago